Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Robert M. Dean"'
Autor:
Beth Faiman, Christy J. Samaras, Jason Valent, Matt Kalaycio, Hien D. Liu, Navneet S. Majhail, Rajshekhar Chakraborty, Robert M. Dean, Jack Khouri, Lisa Rybicki, Jacqulyn Tomer
Publikováno v:
American Journal of Hematology. 94:439-445
Response rate and survival in multiple myeloma (MM) has improved in the era of proteasome inhibitors and immunomodulatory drugs. However, most patients eventually relapse with biochemical progression (BP) alone or with clinical features of end-organ
Autor:
Robert M. Dean, Ehsan Malek, Hien Liu, Janice Reed, Wei Wei, Erica L. Campagnaro, Beth Faiman, Sherry Fada, Jason Valent, Kimberly Hamilton, Ronald Sobecks, Babal K. Jha, Matt Kalaycio, Jack Khouri, Mohammed S. Orloff, Reda Z. Mahfouz, Mary Ann Karam, Yap Chew, Christy J. Samaras, Frederic J. Reu, Yogen Saunthararajah, Dale Grabowski, Hillard M. Lazarus, Shahper N. Khan
Publikováno v:
Seminars in hematology. 58(1)
The DNA methyltransferase inhibitor azacytidine (aza) may reactivate pathways associated with plasma cell differentiation, cell cycle control, apoptosis, and immune recognition and thereby restore sensitivity to lenalidomide (len) and dexamethasone (
Autor:
Betty K. Hamilton, Matt Kalaycio, Robert M. Dean, Deepa Jagadeesh, Lisa Rybicki, Edward A. Copelan, Seth J. Rotz, Rabi Hanna, Taylor Lucas, Donna Corrigan, Brian T. Hill, Brad Pohlman, Aaron T. Gerds, Navneet S. Majhail
Publikováno v:
Blood. 138:99-99
Background: Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT). The combination of tacrolimus (Tac) and methotrexate (MTX) is a standard regimen for GVHD prophyl
Autor:
Yazan F. Madanat, Brian T. Hill, Lisa Rybicki, Tomas Radivoyevitch, Mitchell R. Smith, Brad Pohlman, Robert M. Dean, Mikkael A. Sekeres, Deepa Jagadeesh, Matt Kalaycio
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:857-862
Hairy cell leukemia (HCL) is a rare hematologic malignancy with high response rates and long progression-free survival (PFS) after treatment with purine nucleoside analogs (PNAs; Pentostatin/Cladribine). However, treatment is not curative, and subseq
Autor:
Rabi Hanna, Donna Abounader, Navneet S. Majhail, Mayur Narkhede, Brian J. Bolwell, Brad Pohlman, Aaron T. Gerds, Brian T. Hill, Robert M. Dean, Hien D. Liu, Ronald Sobecks, Matt Kalaycio, Betty K. Hamilton, Lisa Rybicki, Deepa Jagadeesh
Publikováno v:
American Journal of Hematology. 92:683-688
Consensus criteria are routinely used to clinically grade acute graft-versus-host disease (GVHD). A histologic grading system for acute GVHD is available, but there are limited data on its correlation with clinical grade and hematopoietic cell transp
Autor:
Stanton L. Gerson, Adam G. Starr, Howard J. Meyerson, Mira R. Massoud, Paolo Caimi, Deepa Jagadeesh, Pingfu Fu, Eric D. Hsi, Arun D. Singh, Brenda W. Cooper, Robert M. Dean, Brian T. Hill, David B. Mansur, Mitchell R. Smith, Brad Pohlman, Marcos de Lima, Hillard M. Lazarus, Basem M. William, Sheen Cherian
Publikováno v:
British Journal of Haematology. 173:404-412
Extranodal marginal zone lymphoma (EMZL) is a B-cell lymphoma arising from mucosa-associated lymphoid tissue (MALT). The disease characteristics, clinical course and treatment vary considerably based on site of involvement. Because long-term outcome
Autor:
Robert M. Dean, Matt Kalaycio, Donna Abounader, Hien K. Duong, Lisa Rybicki, Brian J. Bolwell, Brian T. Hill, Betty K. Hamilton, Ronald Sobecks, Navneet S. Majhail, Rabi Hanna, Edward A. Copelan, Housam Haddad
Publikováno v:
American Journal of Hematology. 90:144-148
Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in allogeneic hematopoietic cell transplantation (HCT) despite current prophylaxis. Methotrexate (MTX) with a calcineurin inhibitor (CNI) is the current standard, howev
Autor:
Moaath Mustafa Ali, Deepa Jagadeesh, Brian T. Hill, Eric D. Hsi, Robert M. Dean, Laila Nomani, Basel Rouphail, Lisa Rybicki, Mitchell R. Smith, Brad Pohlman
Publikováno v:
Clinical lymphoma, myelomaleukemia. 17(12)
Background Follicular lymphoma (FL) is heterogeneous. Although FL Grade 3B (FL3B) is treated as aggressive FL (aggFL), an optimal approach to FL Grade 3A (FL3A) remains unclear because few data exist on clinical outcomes on the basis of subclassifica
Autor:
James M. Church, Robert M. Dean, Solomon O. Agbroko, Meagan Costedio, Alexander Hallac, Xiuli Liu, Jacob A. Petrosky
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 15(7)
Autor:
Ronald Sobecks, Jerome B. Zeldis, Matt Kalaycio, Janice Reed, Aleksandr Lazaryan, Steven Andresen, Rachid Baz, Kimberly Hamilton, Beth Faiman, Mary Ann Karam, Joel Waksman, Gordan Srkalovic, Frederic J. Reu, John Sweetenham, Robert M. Dean, Robert Knight, Becky Habecker, Kellie Bruening, Mohamad A. Hussein
Publikováno v:
American Journal of Hematology. 89:349-354
A previous interim report of MM-011, the first study that combined lenalidomide with anthracycline-based chemotherapy followed by lenalidomide maintenance for relapsed and/or refractory multiple myeloma (RRMM), showed promising safety and activity. W